Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1986 Dec;49(12):1374–1377. doi: 10.1136/jnnp.49.12.1374

Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.

J Jolkkonen, H Soininen, T Halonen, A Ylinen, V Laulumaa, M Laakso, P Riekkinen
PMCID: PMC1029121  PMID: 2433403

Abstract

Acetylcholinesterase, somatostatin-like immunoreactivity, and homovanillic acid levels were measured in the cerebrospinal fluid of 36 patients with early stages of Parkinson's disease and in 19 control patients. In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in the controls (p less than 0.01); these values were lowest in the demented Parkinsonian patients. Concentrations of homovanillic acid were also significantly lower in Parkinsonian patients (p less than 0.05). In contrast, no changes were observed in the acetylcholinesterase activity of patients with Parkinson's disease. The reduced somatostatin-like immunoreactivity in CSF agrees with previous post-mortem studies and indicates that Parkinson's disease and Alzheimer's disease may have some neurochemical features in common.

Full text

PDF
1374

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvord E. C., Jr, Forno L. S., Kusske J. A., Kauffman R. J., Rhodes J. S., Goetowski C. R. The pathology of Parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv Neurol. 1974;5:175–193. [PubMed] [Google Scholar]
  2. Appleyard M. E., Smith A. D., Wilcock G. K., Esiri M. M. Decreased CSF acetylcholinesterase activity in Alzheimer's disease. Lancet. 1983 Aug 20;2(8347):452–452. doi: 10.1016/s0140-6736(83)90409-9. [DOI] [PubMed] [Google Scholar]
  3. Boller F., Mizutani T., Roessmann U., Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol. 1980 Apr;7(4):329–335. doi: 10.1002/ana.410070408. [DOI] [PubMed] [Google Scholar]
  4. Brown R. G., Marsden C. D. How common is dementia in Parkinson's disease? Lancet. 1984 Dec 1;2(8414):1262–1265. doi: 10.1016/s0140-6736(84)92807-1. [DOI] [PubMed] [Google Scholar]
  5. Davies P., Katzman R., Terry R. D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature. 1980 Nov 20;288(5788):279–280. doi: 10.1038/288279a0. [DOI] [PubMed] [Google Scholar]
  6. Davies P., Maloney A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. doi: 10.1016/s0140-6736(76)91936-x. [DOI] [PubMed] [Google Scholar]
  7. Dubois B., Ruberg M., Javoy-Agid F., Ploska A., Agid Y. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res. 1983 Dec 12;288(1-2):213–218. doi: 10.1016/0006-8993(83)90096-3. [DOI] [PubMed] [Google Scholar]
  8. Dupont E., Christensen S. E., Hansen A. P., de Fine Olivarius B., Orskov H. Low cerebrospinal fluid somatostatin in Parkinson disease: an irreversible abnormality. Neurology. 1982 Mar;32(3):312–314. doi: 10.1212/wnl.32.3.312. [DOI] [PubMed] [Google Scholar]
  9. ELLMAN G. L., COURTNEY K. D., ANDRES V., Jr, FEATHER-STONE R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88–95. doi: 10.1016/0006-2952(61)90145-9. [DOI] [PubMed] [Google Scholar]
  10. Epelbaum J., Ruberg M., Moyse E., Javoy-Agid F., Dubois B., Agid Y. Somatostatin and dementia in Parkinson's disease. Brain Res. 1983 Nov 14;278(1-2):376–379. doi: 10.1016/0006-8993(83)90277-9. [DOI] [PubMed] [Google Scholar]
  11. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hakim A. M., Mathieson G. Dementia in Parkinson disease: a neuropathologic study. Neurology. 1979 Sep;29(9 Pt 1):1209–1214. doi: 10.1212/wnl.29.9_part_1.1209. [DOI] [PubMed] [Google Scholar]
  13. Heston L. L. Dementia associated with Parkinson's disease: a genetic study. J Neurol Neurosurg Psychiatry. 1980 Sep;43(9):846–848. doi: 10.1136/jnnp.43.9.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  15. Hornykiewicz O., Kish S. J. Neurochemical basis of dementia in Parkinson's disease. Can J Neurol Sci. 1984 Feb;11(1 Suppl):185–190. doi: 10.1017/s0317167100046382. [DOI] [PubMed] [Google Scholar]
  16. Hughes C. P., Berg L., Danziger W. L., Coben L. A., Martin R. L. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566–572. doi: 10.1192/bjp.140.6.566. [DOI] [PubMed] [Google Scholar]
  17. Mefford I. N. Application of high performance liquid chromatography with electrochemical detection to neurochemical analysis: measurement of catecholamines, serotonin and metabolites in rat brain. J Neurosci Methods. 1981 Feb;3(3):207–224. doi: 10.1016/0165-0270(81)90056-x. [DOI] [PubMed] [Google Scholar]
  18. Perry E. K., Tomlinson B. E., Blessed G., Bergmann K., Gibson P. H., Perry R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978 Nov 25;2(6150):1457–1459. doi: 10.1136/bmj.2.6150.1457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Perry R. H., Tomlinson B. E., Candy J. M., Blessed G., Foster J. F., Bloxham C. A., Perry E. R. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983 Oct 1;2(8353):789–790. doi: 10.1016/s0140-6736(83)92317-6. [DOI] [PubMed] [Google Scholar]
  20. Pezzoli G., Panerai A. E., Di Giulio A., Longo A., Passerini D., Carenzi A. Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology. 1984 Apr;34(4):516–519. doi: 10.1212/wnl.34.4.516. [DOI] [PubMed] [Google Scholar]
  21. Ruberg M., Ploska A., Javoy-Agid F., Agid Y. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res. 1982 Jan 28;232(1):129–139. doi: 10.1016/0006-8993(82)90615-1. [DOI] [PubMed] [Google Scholar]
  22. Rubinow D. R., Gold P. W., Post R. M., Ballenger J. C., Cowdry R., Bollinger J., Reichlin S. CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983 Apr;40(4):409–412. doi: 10.1001/archpsyc.1983.01790040063009. [DOI] [PubMed] [Google Scholar]
  23. Soininen H. S., Jolkkonen J. T., Reinikainen K. J., Halonen T. O., Riekkinen P. J. Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci. 1984 Feb;63(2):167–172. doi: 10.1016/0022-510x(84)90193-x. [DOI] [PubMed] [Google Scholar]
  24. Sørensen K. V., Christensen S. E., Dupont E., Hansen A. P., Pedersen E., Orskov H. Low somatostatin content in cerebrospinal fluid in multiple sclerosis. An indicator of disease activity? Acta Neurol Scand. 1980 Mar;61(3):186–191. doi: 10.1111/j.1600-0404.1980.tb01481.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES